🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age

RecruitingPhase 3Ages 18 Years - 50 YearsFemaleJimma University
NCT06250257 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Dilated cardiomyopathy (DCM) is a condition associated with left and /or right ventricular (LV) dilatation and systolic dysfunction without coronary artery disease or abnormal loading circumstances proportionate to the severity of LV impairment. It is one of the leading causes of heart failure in younger adults. About 35% of patients have genetic mutations affecting cytoskeletal, sarcomere, and nuclear envelope proteins while others are idiopathic and possibly complications of myocarditis. Recently, in patients with peripartum cardiomyopathy (PPCM)-a subtype of dilated cardiomyopathy, high levels of prolactin and its degradation by-products including a cleaved 16kDa N-terminal fragment have emerged as key factors in the pathophysiology. The 16kDa prolactin induces profound endothelial damage and subsequent cardiomyocyte dysfunction and hence heart failure. Bromocriptine has been studied

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Women age 18 years to 50 years and * ischemic or de novo dilated cardiomyopathy Exclusion Criteria: * Patients with severe comorbidities which may worsen their illness * with hypertensive heart diseases * Rheumatic valvular heart diseases * Restrictive cardiomyopathy, constrictive cardiomyopathy, hypertrophic cardiomyopathy * Congenital heart diseases * Acute coronary syndrome * Overt kidney failure (serum Creatinine ≥ 1.4mg/dl), * Women who had history of peripartal cardiomyopathy, are pregnant or planning pregnancy during the study period or lactating * Previous adverse reaction to the bromocriptine * Patients not willing to participate in the study
💊

What it tests

  • Bromocriptine mesylate plus standard GDMT
📍

Where

1 site
Jimma Medical Center
Jimma, Ethiopia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy